[Esophageal Cancer and Gut Microbiome]

The gut microbiota has recently garnered considerable attention across the medical field, as its involvement has been reported in a broad spectrum of conditions including cancer, obesity, inflammatory bowel disease, and even neuropsychiatric disorders. The human body is composed of approximately 30 trillion human cells and an almost equal number of bacterial cells, forming a highly integrated symbiotic relationship. While the human genome encodes only about 20,000 genes, the gut microbiota harbors several million to tens of millions of genes, offering an overwhelmingly greater genetic repertoire. The composition of the microbiota is influenced by diet, lifestyle, medications, and aging, thereby shaping unique individual - specific patterns. Regional and temporal variations are also recognized, and functional redundancy among different bacterial taxa, known as"functional mimicry,"further underscores its flexibility. Thus, the gut microbiota should be regarded as a dynamic and modifiable ecosystem rather than a fixed entity, making it a promising target for disease prevention and therapeutic intervention. In the context of esophageal cancer, emerging evidence indicates that alterations in the microbiota may affect carcinogenesis, disease progression, and therapeutic responses. These insights highlight the potential of the microbiota as both a biomarker and a therapeutic target, and suggest that integrating microbiome research into clinical oncology could open new avenues for improving patient outcomes.